SEC Form 4 · accession 0000950138-17-000353
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank Scholz
Officer — EVP Glob Ops & Pres Spec Gen
Period of report
Apr 1, 2017
Accepted (ET)
Apr 4, 2017 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Apr 1, 2017 | A | 5,588 | $0.00 | A | 44,297 | D | |
| Ordinary Shares | Apr 1, 2017 | F | 2,346 | $44.57 | D | 41,951 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Vesting of performance share award granted on April 1, 2014.
- F2Includes 147 shares acquired on December 31, 2016 under the Mallinckrodt employee stock purchase plan.